[Wiley] Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome

hanumanth Post time 2023-2-1 14:06:46 | Show all posts |Read mode
Reward10points

journal£ºJournal of Clinical Pharmacy and Therapeutics

Authors£ºBradley P. Dixon; Ashley Sabus

Published date£º2022-7-

DOI£º10.1111/jcpt.13642

Article link£ºhttp://dx.doi.org/10.1111/jcpt.13642

Article Source£ºHindawi Limited¡£


Remark£º

Best Answer

Please adopt

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
David Post time 2023-2-1 14:06:47 | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report


Senior Member
  • post

  • reply

  • points

    4290

Latest Reply



Return to the list